Evidence map›Paper›PMID 26982577›Full record

ReviewAmerican journal of respiratory cell and molecular biology2016

Heparan Sulfate in the Developing, Healthy, and Injured Lung.

Sarah M Haeger, Yimu Yang, Eric P Schmidt

Open access · greenAbstract readReview
In one paragraph

Review in American journal of respiratory cell and molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Enzymatic Modulation of the Pulmonary Glycocalyx Enhances Susceptibility toAmerican journal of respiratory cell and molecular biology · 2024
    Article
  7. Article
  8. Tunneling Nanotubes: The Cables for Viral Spread and Beyond.Results and problems in cell differentiation · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Proteoglycans: a common portal for SARS-CoV-2 and extracellular vesicle uptake.American journal of physiology. Cell physiology · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sarah M Haeger1 Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado; and.
Yimu Yang1 Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado; and.
Eric P Schmidt1 Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado; and.
University of Colorado Denver · USDenver Health Medical Center · US

Funding

Medical Scientist Training ProgramT32GM008497 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI WILSON, CARA C. · 1993 to 2022
$15.2M
PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM007635 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 1985 to 2023
$6.1M
Endothelial glycocalyx reconstitution during sepsisR01HL125371 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI LINHARDT, ROBERT J, SCHMIDT, ERIC PETER · 2014 to 2018
$3.4M
Heparan Sulfate Fragments and Lung RepairF30HL132424 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI HAEGER, SARAH MARIE · 2016 to 2018
$116k
NHLBI NIH HHS F30 HL132424NHLBI NIH HHS R01 HL125371NIGMS NIH HHS T32 GM007635NIGMS NIH HHS T32 GM008497
6 · The paper itself

Abstract

Remarkable progress has been achieved in understanding the regulation of gene expression and protein translation, and how aberrancies in these template-driven processes contribute to disease pathogenesis. However, much of cellular physiology is controlled by non-DNA, nonprotein mediators, such as glycans. The focus of this Translational Review is to highlight the importance of a specific glycan polymer-the glycosaminoglycan heparan sulfate (HS)-on lung health and disease. We demonstrate how HS contributes to lung physiology and pathophysiology via its actions as both a structural constituent of the lung parenchyma as well as a regulator of cellular signaling. By highlighting current uncertainties in HS biology, we identify opportunities for future high-impact pulmonary and critical care translational investigations.

Indexed as

Acute DiseaseAnimalsChronic DiseaseHeparan SulfateHumansLungLung InjurySignal TransductionHeparan Sulfateglycocalyxglycosaminoglycanheparan sulfateproteoglycan

Identifiers

PMID26982577
PMCPMC4942210
OpenAlexW2298105916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.